Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
Financing and global licensing deal to accelerate phase 2b development of AP306
Original title: “R1 Therapeutics launches with $77.5m to advance hyperphosphatemia treatment”
Collaboration aims to streamline and scale next‑generation Treg therapy production
Original title: “Taiwan Bio partners with Terumo to advance automated Treg manufacturing”
Astellas Pharma and CytomX Therapeutics first partnered up in March 2020. For $80 million upfront, the Japanese pharma gained access to the biotech’s Probody platform to generate masked antibody therapies for cancer.
Original title: “Astellas Divorces CytomX Despite Positive Phase 1 Data for Antibody Platform”
The startup believes a pill it licensed from a Chinese biotech company could be more potent, and convenient to take, than existing treatments for a common complication of chronic kidney disease.
Original title: “R1 starts up with $78M, aiming for a better kidney drug”
In a highly competitive space, AI platforms must now prove themselves through proprietary data, focused pipelines and clinical readouts in competitive diseases. Promises of faster, cheaper drug discovery are not enough to entice strong investor engagement.
Original title: “AI Drug Discovery Platforms Face New Investor Bar”
Sarepta has begun evaluating a regimen meant to lower the risk of liver damage in Elevidys recipients. Elsewhere, Inovio laid off staff and a Bayer kidney drug notched another trial victory.
Original title: “Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy”
Dozens of biotechs reported earnings this week. BioSpace recaps key highlights from Capricor Therapeutics, Legend Biotech, Inovio and Allogene.
Original title: “Biotechs Report Regulatory Headaches, High-Stakes Catalysts During Q4 Earnings”
Evotec will cut 800 employees in its second layoff round since 2024. Elsewhere, Ultragenyx got a needed win and a twice-rejected cell therapy is getting an audience at the FDA.
Original title: “Evotec, Vistagen lay off staff; Immutep shares collapse on study failure”
Small-molecule drugs account for nearly half of the most valuable investigational therapies for orphan diseases, according to analytics firm Evaluate.
Original title: “Rare Disease Sales To Soar to $400B+ By 2032 as Small Molecules Resurgent: Evaluate”
Total assets under management for Novo Holdings, Novo Nordisk’s controlling shareholder, fell by more than one-third last year. The report caps off a tumultuous year for the Novo group of companies.
Original title: “Novo Holdings’ Assets Fell 34% in 2025 As Its Namesake Drugmaker Struggled”
Follow here for all the latest news about mergers, acquisitions and joint partnerships in the healthcare industry.
Original title: “Healthcare deals: Live updates on mergers and acquisitions - Modern Healthcare”
The chief executives of AbbVie and Johnson & Johnson are now among the highest-paid pharma leaders after pay bumps pushed their 2025 compensations past $30 million.
Original title: “J&J, AbbVie CEOs See Pay Spike to More Than $30M”
Last month, for the first time in nearly four years, average job postings live on BioSpace did not decline year over year. In another encouraging sign, the number of biopharmas letting employees go fell.
Original title: “Hiring Outlook: February Brings First YOY Job Increase Since 2022”
The Los Angeles region is one of California’s fastest-growing life sciences hubs, according to a California Life Sciences sector report. The CEO of BioscienceLA discusses the market’s strengths, challenges and where it might be five years from now.
Original title: “The Next Cambridge? LA Sets Its Sights Higher”
Buyers are joining special purpose vehicles to get a piece of the hottest companies before they go public. Sometimes the funds don’t actually own any shares. Sometimes the funds don’t actually own any shares. ... From Silicon Valley to Wall Street to the City of London, financial elites are hitting up their wealth managers and plugged-in friends for a way into SpaceX and OpenAI. What they’re seeking is access to special purpose vehicles, which hold coveted private shares in such firms. For companies whose valuations in an IPO can be as much as double their most recent funding round, even investors who effectively own fractions of shares are potentially in line for a windfall.
Original title: “SpaceX, OpenAI Potential Blockbuster IPOs Lure Investors Into Murky Deals”
The Zepbound developer is joining other drugmakers’ rush into China as it plans to boost its oral solid dosage supply chain to support the launch of its obesity pill orforglipron.
Original title: “Lilly unveils $3 billion production expansion in China”
Looking for a biopharma job in Cambridge? Check out the BioSpace list of six companies hiring life sciences professionals like you.
Original title: “6 Companies Hiring in Cambridge”
Orforglipron, Eli Lilly’s oral obesity drug, is under FDA review with a decision expected in April. The pharma has also filed for marketing authorization for the pill in China.
Original title: “Lilly Pumps $3B Into China To Boost Supply of Weight Loss Pill”
Incubated by Atlas Venture, the biotech startup is advancing a daily pill it sees potentially helping people with dystonia or Parkinson's disease regain control of movement.
Original title: “With $100M, Vima pursues an oral drug for movement disorders”
A string of successful initial public offerings by Korean biotech companies this year reflects a shift toward firms with proven revenue and technology licensing A string of successful initial public offerings by Korean biotech companies this year reflects a shift toward firms with proven revenue and technology licensing track records seeking KOSDAQ listings. Institutional competition ratio alone is 1000 to 1... Companies with trillion-won-level technology transfers also lining up · Companies that have secured trillion-won-scale technology transfer contracts are now entering the stock market, fueling the IPO boom in the biotech sector. Industry observers say the sector is advancing as biotech firms secure funding based on concrete results rather than speculative expectations about drug development. Expectations are rising for biotech companies preparing to go public. Ingenia Therapeutics, a Boston-based biotech firm, filed for a KOSDAQ preliminary listing review on January 30. The company develops treatments for ocular retinal diseases and glaucoma. The non-refundable upfront payment alone reached $80 million (about 118 billion won)—the highest upfront-to-total-value ratio (7.7%) among Korean pharmaceutical and biotech licensing deals signed last year. Adel is currently conducting pre-IPO fundraising and preparing for a technology evaluation for a special tech-based listing next month. A biotech industry official said, "Korean biotech companies faced funding difficulties after 2022 due to conservative investment from venture capital, with many withdrawing IPO plans." The official added, "But recently, companies with concrete track records are pursuing listings, improving the funding environment for biotech firms."
Original title: “K-Bio IPOs Surge as Tech Licensing Deals Reach Trillion-Won Scale - Seoul Economic Daily”